Interference with the renin-angiotensin system in heart failure

Baker CS, Dutka DP, Pagano D, Rimoldi O, Pitt M, Hall RJ, Polak JM, Bonser RS, Camici PG (2002) Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium. Basic Res Cardiol 97:409–415

Balcells E, Meng QC, Johnson WH, Jr., Oparil S, Dell’Italia LJ (1997) Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273:H1769–H1774

Baumgarten CR, Linz W, Kunkel G, Scholkens BA, Wiemer G (1993) Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 108:293–295

Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 1658:44–49

Burrell LM, Johnston CI, Tikellis C, Cooper ME (2004) ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15:166–169

Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI (2005) Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26:369–375

Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD (2004) Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 22:1971–1976

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9

Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581

Frolkis I, Gurevitch J, Yuhas Y, Iaina A, Wollman Y, Chernichovski T, Paz Y, Matsa M, Pevni D, Kramer A, Shapira I, Mohr R (2001) Interaction between paracrine tumor necrosis factor-alpha and paracrine angiotensin II during myocardial ischemia. J Am Coll Cardiol 37:316–322

Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2:19

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776

Gring CN, Francis GS (2004) A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol 44:1841–1846

Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD (2003) Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 163:1574–1579

Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I (1999) Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100:2093–2099

Holtz J (1998) Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Basic Res Cardiol 93(Suppl 2):92–100

Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970–976

Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G (1998) Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32:1787–1796

Kalra D, Sivasubramanian N, Mann DL (2002) Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 105:2198–2205

Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z (2005) Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97:946–953

Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H (2001) Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. Atherosclerosis 156:255–265

Lijnen PJ, Petrov VV (2003) Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. Methods Find Exp Clin Pharmacol 25:541–564

Liu YH, Xu J, Yang XP, Yang F, Shesely E, Carretero OA (2002) Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 39:375–381

Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA (2000) Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol 278:H507–H514

Liu YH, Yang XP, Shesely EG, Sankey SS, Carretero OA (2004) Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol 43:1473–1480

Lopez-Farre A, Sanchez de ML, Monton M, Jimenez A, Lopez-Bloya A, Gomez J, Nunez A, Rico L, Casado S (2001) Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 16(Suppl 1):45–49

McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771

Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA (2005) Chronic infusion of angiotensin-(1–7) reduces heart angiotensin II levels in rats. Regul Pept 125:29–34

Mielniczuk L, Stevenson LW (2005) Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials? Curr Opin Cardiol 20:250–255

Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjoquist PO, Abrahamsson T (1999) Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 33:1406–1413

Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology. Eur Heart J 26:384–416

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759–766

Rosenkranz S (2004) TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63:423–432

Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K (2005) C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 7:748–754

Schafer A, Fraccarollo D, Tas P, Schmidt I, Ertl G, Bauersachs J (2004) Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur J Heart Fail 6:151–159

Scheubel RJ, Tostlebe M, Simm A, Rohrbach S, Prondzinsky R, Gellerich FN, Silber RE, Holtz J (2002) Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J Am Coll Cardiol 40:2174–2181

Schulz R, Aker S, Belosjorow S, Heusch G (2004) TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 99:8–11

Schulz R, Heusch G (2003) AT1-receptor blockade in experimental myocardial ischemia/reperfusion. Clin Nephrol 60(Suppl 1): S67–S74

Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL (2005) Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 108(3): 225–256

Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA (2001) Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88:961–968

Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Onozuka H, Mikami T, Kumamoto H, Kitabatake A (2002) Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J 43:531–543

Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R (2002) Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360:1037–1043

Timmermans PB (1999) Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 15(Suppl F):26F–28F

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M (2000) Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35:714–721

Tsutamoto T, Wada A, Ohnishi M, Tsutsui T, Ishii C, Ohno K, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Dohke T, Horie M (2004) Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. Eur J Heart Fail 6:173–180

Unger T (1999) Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 84:9S–15S

Urata H, Ganten D (1993) Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase. Eur Heart J 14(Suppl I):177–182

Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macri G, Mastrorilli F, Paolini M, Ferrari R (2004) Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. J Am Coll Cardiol 43:2000-2008

Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G (2000) Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol 131:138–144

Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, Cohn JN (2004) Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 43:2022–2027

Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP (2002) Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40:244–250

Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA (2001) Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 88:1072–1079